These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25773279)

  • 21. Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
    Currie CJ; Holden SE
    Diabetes Obes Metab; 2014 Oct; 16(10):881-4. PubMed ID: 25040702
    [No Abstract]   [Full Text] [Related]  

  • 22. Insulin initiation in Type 2 diabetes.
    Page S
    Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
    [No Abstract]   [Full Text] [Related]  

  • 23. [Combination therapy of oral hypoglycemic agents which enhance the efficacy of insulin therapy].
    Hirose T
    Nihon Rinsho; 2012 May; 70 Suppl 3():669-77. PubMed ID: 22768596
    [No Abstract]   [Full Text] [Related]  

  • 24. The UK Prospective Diabetes Study.
    Kerner W
    Lancet; 1998 Dec; 352(9144):1934. PubMed ID: 9863811
    [No Abstract]   [Full Text] [Related]  

  • 25. [Fear of the injection must not be an argument. Every second type 2 diabetic patient needs insulin].
    MMW Fortschr Med; 2002 Dec; 144(49):60. PubMed ID: 12577748
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
    Morton AP; McIntyre HD
    Med J Aust; 2005 May; 182(9):492-3. PubMed ID: 15865597
    [No Abstract]   [Full Text] [Related]  

  • 27. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
    [No Abstract]   [Full Text] [Related]  

  • 28. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
    McAlister FA; Eurich DT; Majumdar SR; Johnson JA
    Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A family with a novel termination mutation in hepatic nuclear factor 1α in maturity-onset diabetes of the young type 3 which is unresponsive to sulphonylurea therapy.
    Demol S; Lebenthal Y; Bar-Meisels M; Phillip M; Gat-Yablonski G; Gozlan Y
    Horm Res Paediatr; 2014; 81(4):280-4. PubMed ID: 24642958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Delayed sulfonylurea resistance in non-insulin-dependent diabetes mellitus].
    Farkas K; Jermendy G; Somogyi A
    Orv Hetil; 1997 Nov; 138(48):3031-5. PubMed ID: 9441264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressing From Metformin to Sulfonylureas or Meglitinides.
    Grant JS; Graven LJ
    Workplace Health Saf; 2016 Sep; 64(9):433-9. PubMed ID: 27621259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents.
    Davidson MB
    West J Med; 1992 Aug; 157(2):199-200. PubMed ID: 1441492
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral hypoglycaemic agents. When, how and why.
    Harris P; Colagiuri S
    Aust Fam Physician; 1997 Apr; 26(4):391-6. PubMed ID: 9115112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 diabetes: which drug as add-on to metformin?
    Madsbad S
    Lancet; 2012 Jun; 379(9833):2222-3. PubMed ID: 22683136
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment choices for managing hyperglycaemia in patients with type 2 diabetes and moderate to severe renal disease.
    Palmer F; Prior SL; Mallipedhi A; Jones DA; Price DE; Stephens JW
    Diabetes Res Clin Pract; 2012 Aug; 97(2):e23-4. PubMed ID: 22776145
    [No Abstract]   [Full Text] [Related]  

  • 36. Exorcising the specter of nighttime hypoglycemia.
    Scheiner G
    Diabetes Self Manag; 2012; 29(1):16, 18-20. PubMed ID: 22482132
    [No Abstract]   [Full Text] [Related]  

  • 37. [Guidelines of the Swiss Diabetic Association concerning oral antidiabetic agents].
    Pernet A; Bäbler M; Ganz K
    Schweiz Rundsch Med Prax; 1986 May; 75(21):626-8. PubMed ID: 3726361
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 39. [Metformin--its regimen and effects].
    Shiba T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():382-8. PubMed ID: 12387022
    [No Abstract]   [Full Text] [Related]  

  • 40. Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?
    Ahluwalia R; Perkins K; Ewins D; Goenka N
    Diabet Med; 2009 Aug; 26(8):834-5. PubMed ID: 19709161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.